Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly EBT Margin came in at 23033.9% in Q4 2025, down 468754.0% YoY from N/an in Q4 2024, and down 25.55% on a QoQ basis from 18346.35% in Q4 2024.
Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 10 years of EBT Margin data on file, last reported at 23033.9% in Q4 2025.
- Quarterly EBT Margin fell 468754.0% year-over-year to 23033.9% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15618.8% (down 767889.0% YoY) and the FY2025 annual result came in at 132362.71%, down 12442280.0% from the prior year.
- EBT Margin fell to 23033.9% in Q4 2025, from 18346.35% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 9246.18% in Q3 2024 to a low of 23033.9% in Q4 2025.
- A 5-year average of 4024.64% and a median of 1432.05% in 2023 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 1145805 bps in 2024, down 1691431 bps in 2024.
- Tracing AVTX's EBT Margin over 5 years: stood at 8742.92% in 2021, then surged by 87 bps to 1094.2% in 2022, then tumbled by 31 bps to 1432.05% in 2023, then sank by 1181 bps to 18346.35% in 2024, then retreated by 26 bps to 23033.9% in 2025.
- The last three EBT Margin figures came in at 23033.9% (Q4 2025), 18346.35% (Q4 2024), and 9246.18% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23,033.90% |
| Dec 31, 2024 | -18,346.35% |
| Sep 30, 2024 | 9,246.18% |
| Dec 31, 2023 | -1,432.05% |
| Sep 30, 2023 | -2,211.86% |
| Jun 30, 2023 | -1,273.09% |
| Mar 31, 2023 | -2,094.11% |
| Dec 31, 2022 | -1,094.20% |
| Sep 30, 2022 | 21.39% |
| Jun 30, 2022 | -1,256.73% |
| Mar 31, 2022 | -1,879.11% |
| Dec 31, 2021 | -8,742.92% |
| Sep 30, 2021 | -1,293.56% |
| Jun 30, 2021 | -517.82% |
| Mar 31, 2021 | -6,461.52% |
| Dec 31, 2020 | -1,090.71% |
| Sep 30, 2020 | -1,193.34% |
| Jun 30, 2020 | -992.53% |
| Mar 31, 2020 | -882.79% |
| Dec 31, 2019 | -141.58% |